Nisha Poddar
-
Tata Trusts To 'Evaluate Action' If Chandra-Venu Conflict Of Interest Allegations Are Proven True
Tata Trusts told NDTV Profit that if these allegations were proven to be true, it will evaluate response and act appropriately.
-
AI Efficiency Is Only Half The Story: Anthropic India MD On What Comes Next
Companies adopting AI should measure not only efficiency gains but also whether the capacity created is being used to drive innovation and growth, Irina Ghose said.
-
HDFC Bank Considers Kaizad Bharucha, Jimmy Tata As Internal Candidates For CEO: Sources
"HDFC Bank may have communicated the 2 internal candidates' names for CEO to the Reserve Bank of India," the sources informed on the condition of anonymity.
-
NSE IPO: Self-Listing Barred, But PTT Route May Open A Back Door
SEBI may need to weigh in as NSE eyes the "permitted to trade" window to list on rival BSE while still trading on its own platform.
-
Tata Sons AGM Called Off Due To Lack Of Quorum
The AGM was held against the backdrop of Tata Sons Chairman N Chandrasekaran deciding not to seek another term at the helm of the holding company.
-
Zepto Delays IPO After Lukewarm MF Response, Pivots To Rs 1,000 Crore Fundraise: Sources
Zepto plans to update its financials and then go back to market to launch its public issue, persons privy to the development said.
-
Delhivery CEO Explains How They Tackle The Threat From In-House Logistics
In an exclusive interview with NDTV Profit, Sahil Barua said nearly 100% of freight contracts are fuel-cost protected, ruling out any long-term hit to margins from elevated crude oil prices.
-
Nifty Braces For 23,000 Test As AI Jitters, Iran War-Led Energy Shock Rattles D-Street: Manishi Raychaudhari
Emmer Capital's Raychaudhari outlined the current complex macroeconomic environment where global tech jitters, energy price spikes, and domestic inflation risks are converging to test investor resilience.
-
Manipal Hospital IPO 'Just An Event'; Temasek Bullish On Healthcare Run: Ravi Lambah
Temasek's Lambah noted that investment momentum remains strictly on track, with plans to deploy approximately $10 billion in India
-
Reliance Industries Promoters Raise Stake to 50% After Rs 9,000 Crore Creeping Acquisition
Promoter holding rose from 49.52% in March to 50% at the end of June after purchases during the first quarter.
-
Biocon's Shaw Reckons Rivals' China Reliance Gives It the Edge in GLP-1 Race
In an exclusive interview to NDTV Profit, Biocon founder, Kiran Mazumdar-Shaw, also said that insulin "will never go away" and defended company's low-margin bet.
-
Biocon's Shaw Pitches DNA-Based Data Centres as Answer to AI's Energy Problem
In an exclusive interview to NDTV Profit, Kiran Mazumdar-Shaw says biology, not silicon, could solve the data centre crunch.
-
Syngene 'Lost Its Way' But Kiran Mazumdar-Shaw Promises Turnaround by Next Fiscal
In an exclusive interview to NDTV Profit, Biocon founder says the CDMO arm strayed from its core strength but is now being rebuilt.
-
Novo Nordisk Launches Once-Weekly Insulin In India; Promises Competitive Pricing, Wider Access
Awiqli cuts basal insulin dosing from seven injections a week to one. Novo Nordisk India MD Vikrant Shrotriya discusses price, access and growth.
-
Tata Trusts Reject Allegations Over 1989 Tata Sons Share Transfer, Threaten Legal Action
The statement was issued in response to a complaint reportedly made to the Charity Commissioner regarding the transfer of Tata Sons shares that took place over three decades ago.
